Abstract
A physiologic additive for dissolving insulin crystals for parenteral application has been found. Insulin crystals are relatively insoluble in simple aqueous solutions. They will dissolve, however, in highly acidic solutions, but these are not suitable for parenteral use. Both neutral and acid pH insulin solutions have a tendency for the dissolved hormone to reaggregate. Notwithstanding possible changes in biologic activity, such formed aggregates must be prevented because they interfere with the flow in portable insulin delivery devices and result in the loss of glycemic control. The addition of 1.5% autologous serum to the aqueous diluent for insulin has eliminated these difficulties and increased by 37% the apparent biologic activity of insulin solutions prepared in this way. With this additive, continuous uninterrupted intravenous insulin infusion has provided near ideal blood glucose control in four pancreatectomized dogs for 5 mo and four patients with juvenile-onset diabetes for 18--23 days. Serum apparently contains factor(s) that promote the dissolution of insulin and prevent the formation of peptide aggregates in dilute solutions.
Citations
Jan 1, 1981·Diabetologia·W D LougheedA M Albisser
Jul 1, 1980·Diabetologia·W D LougheedA M Albisser
Sep 1, 1983·Diabetologia·J Mirouze
Oct 1, 1980·Diabetologia·A B Kurtz, J D Nabarro
Jul 1, 1985·Diabetologia·U Grau
Nov 1, 1980·Diabetologia·Y GoriyaA M Albisser
Jul 1, 1981·Diabetologia·Y GoriyaA M Albisser
Mar 1, 1986·The Journal of Clinical Investigation·M MaislosD C Robbins
Nov 29, 2013·Biomacromolecules·Ashish Kumar AgrawalSanyog Jain
Feb 5, 1988·Journal of Chromatography·E Watson, W C Kenney
Jan 1, 1993·Journal of Drug Targeting·A K Banga, R Mitra
Dec 1, 1983·Journal of Pharmaceutical Sciences·R Quinn, J D Andrade
Mar 1, 1993·Journal of Biomedical Engineering·P Y Wang
Apr 1, 1982·IEEE Transactions on Bio-medical Engineering·A M Albisser, W J Spencer
Mar 1, 1981·IEEE Transactions on Bio-medical Engineering·W J Spencer
Apr 1, 1991·Diabetes Research and Clinical Practice·G AntonyL C Svejkar
Mar 1, 1983·Journal of Pharmaceutical Sciences·S SatoS W Kim
Aug 31, 1989·The New England Journal of Medicine·C D SaudekM A Charles
Apr 1, 1983·Disease-a-month : DM·M Bergman, P Felig
Mar 1, 1990·Journal of Medical Engineering & Technology·D A Linkens, S S Hacisalihzade
Apr 17, 2014·Diabetes Technology & Therapeutics·Pauline SchaepelynckNathalie Jeandidier